Financials HansBiomed Corporation

Equities

A042520

KR7042520007

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. 18:00:00 2024-05-13 EDT 5-day change 1st Jan Change
13,490 KRW +7.06% Intraday chart for HansBiomed Corporation +3.13% -8.11%

Valuation

Fiscal Period: Septiembre 2018 2019 2020 2021 2022 2023
Capitalization 1 295,706 206,744 226,346 160,691 92,964 207,570
Enterprise Value (EV) 1 299,141 214,378 236,330 191,999 135,320 241,663
P/E ratio 75.3 x 21.6 x -12.6 x -8.78 x 53.3 x -8.34 x
Yield 0.32% 0.55% - - - -
Capitalization / Revenue 5.71 x 3.09 x 2.83 x 2.72 x 1.25 x 2.66 x
EV / Revenue 5.78 x 3.2 x 2.95 x 3.25 x 1.82 x 3.1 x
EV / EBITDA 24.5 x 15 x 1,147 x -12.8 x 22 x 232 x
EV / FCF 69.4 x -47 x -35.9 x -51.3 x -8.24 x 122 x
FCF Yield 1.44% -2.13% -2.79% -1.95% -12.1% 0.82%
Price to Book 4.72 x 2.88 x 3.79 x 3.62 x 2.03 x 4.22 x
Nbr of stocks (in thousands) 9,417 9,462 9,906 10,012 9,674 11,577
Reference price 2 31,400 21,850 22,850 16,050 9,610 17,930
Announcement Date 12/19/18 12/18/19 12/18/20 12/21/21 12/20/22 12/19/23
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Septiembre 2018 2019 2020 2021 2022 2023
Net sales 1 51,746 66,991 80,098 59,098 74,459 78,032
EBITDA 1 12,188 14,326 206.1 -14,993 6,158 1,043
EBIT 1 10,308 12,572 -3,407 -19,778 1,256 -4,155
Operating Margin 19.92% 18.77% -4.25% -33.47% 1.69% -5.32%
Earnings before Tax (EBT) 1 5,298 11,484 -16,700 -21,617 3,501 -23,532
Net income 1 4,017 9,951 -17,840 -18,289 6,147 -23,045
Net margin 7.76% 14.85% -22.27% -30.95% 8.26% -29.53%
EPS 2 416.8 1,012 -1,808 -1,827 180.4 -2,150
Free Cash Flow 1 4,309 -4,560 -6,587 -3,746 -16,415 1,977
FCF margin 8.33% -6.81% -8.22% -6.34% -22.05% 2.53%
FCF Conversion (EBITDA) 35.36% - - - - 189.48%
FCF Conversion (Net income) 107.26% - - - - -
Dividend per Share 2 100.0 120.0 - - - -
Announcement Date 12/19/18 12/18/19 12/18/20 12/21/21 12/20/22 12/19/23
1KRW in Million2KRW
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: Septiembre 2023 Q1 2023 Q2 2023 Q3
Net sales 1 20.07 20.48 18.47
EBITDA - - -
EBIT 1 0.0858 -0.3468 0.1217
Operating Margin 0.43% -1.69% 0.66%
Earnings before Tax (EBT) - - -
Net income 1 -3.588 -9.744 -0.4159
Net margin -17.88% -47.57% -2.25%
EPS - - -
Dividend per Share - - -
Announcement Date 2/14/23 5/15/23 8/14/23
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: Septiembre 2018 2019 2020 2021 2022 2023
Net Debt 1 3,435 7,634 9,984 31,309 42,356 34,093
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 0.2819 x 0.5329 x 48.45 x -2.088 x 6.878 x 32.68 x
Free Cash Flow 1 4,309 -4,560 -6,587 -3,746 -16,415 1,977
ROE (net income / shareholders' equity) 7.94% 12.4% -23.7% -37.9% 10.4% -49.5%
ROA (Net income/ Total Assets) 7.49% 6.96% -1.6% -9.46% 0.6% -2.04%
Assets 1 53,625 142,994 1,113,899 193,266 1,022,469 1,127,320
Book Value Per Share 2 6,651 7,592 6,026 4,440 4,732 4,244
Cash Flow per Share 2 872.0 1,055 1,382 704.0 780.0 530.0
Capex 1 2,241 15,564 7,046 4,891 3,986 1,937
Capex / Sales 4.33% 23.23% 8.8% 8.28% 5.35% 2.48%
Announcement Date 12/19/18 12/18/19 12/18/20 12/21/21 12/20/22 12/19/23
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A042520 Stock
  4. Financials HansBiomed Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW